[HTML][HTML] Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD
…, M Montembault, CN Leemereise… - Pulmonary …, 2017 - Elsevier
… accumulation from Day 1 to Day 7, measured by ratio of geometric mean plasma concentration
immediately after dosing, and an approximate 1.2 fold increase from Day 7 to day 14 in C …
immediately after dosing, and an approximate 1.2 fold increase from Day 7 to day 14 in C …
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult …
…, H Crauwels, C Leemereise… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Cabotegravir + rilpivirine administered via intramuscular gluteal injections is the first complete
long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression. The …
long-acting (LA) regimen approved for maintaining HIV-1 virologic suppression. The …
A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of …
…, A Cahn, M Begg, M Montembault, C Leemereise… - … of Pharmacology and …, 2018 - ASPET
Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase involved in leukocyte recruitment and
activation. Activation of PI3Kδ has been linked to airway inflammation and asthma …
activation. Activation of PI3Kδ has been linked to airway inflammation and asthma …
An inhaled PI3Kδ inhibitor improves recovery in acutely exacerbating COPD patients: a randomized trial
…, E Jarvis, R Wilson, G Dear, C Leemereise… - … journal of chronic …, 2021 - Taylor & Francis
Purpose This study evaluated the safety and efficacy of inhaled nemiralisib, a phosphoinositide
3-kinase δ (PI3Kδ) inhibitor, in patients with an acute exacerbation of chronic obstructive …
3-kinase δ (PI3Kδ) inhibitor, in patients with an acute exacerbation of chronic obstructive …
Safety, tolerability, and pharmacokinetics of a new formulation of nemiralisib administered via a dry powder inhaler to healthy individuals
R Wilson, A Templeton, C Leemereise, R Eames… - Clinical Therapeutics, 2019 - Elsevier
… Hessel are GlaxoSmithKline employees and all hold GlaxoSmithKline shares, except for
Claudia Leemereise. Edith M. Hessel is named on patents for compound GSK2269557 (…
Claudia Leemereise. Edith M. Hessel is named on patents for compound GSK2269557 (…
Inhaled PI3Kδ inhibitor Nemiralisib improves lung function and reduces Re-Exacerbations in exacerbating chronic obstructive pulmonary disease (COPD) patients …
…, M Begg, E Jarvis, R Wilson, C Leemereise… - … IN LUNG DISEASE, 2018 - atsjournals.org
RATIONALE More effective therapies that treat acute exacerbations of chronic obstructive
pulmonary disease (COPD) are highly needed. This study evaluated the efficacy, safety and …
pulmonary disease (COPD) are highly needed. This study evaluated the efficacy, safety and …
A33 CLINICAL STUDIES IN OBSTRUCTIVE LUNG DISEASE: Safety, Pharmacokinetics And Dose-Response Characteristics Of Gsk2269557, An Inhaled Pi3kä …
…, M Montembault, C Leemereise… - American Journal of …, 2017 - search.proquest.com
Rationale: While current therapies reduce symptoms in chronic obstructive pulmonary disease
(COPD) patients, substantial unmet need remains. At Day 14, relative to placebo, sputum …
(COPD) patients, substantial unmet need remains. At Day 14, relative to placebo, sputum …
Safety, Pharmacokinetics And Dose-response Characteristics Of GSK2269557, An Inhaled PI3Kδ Inhibitor Under Development For The Treatment Of COPD
…, M Montembault, C Leemereise… - A33. CLINICAL …, 2017 - atsjournals.org
Rationale: remains. This study evaluated safety, pharmacokinetics (PK) and dose-response
characteristics of inhaled GSK2269557, a PI3Kδ inhibitor, in moderate-to-severe COPD …
characteristics of inhaled GSK2269557, a PI3Kδ inhibitor, in moderate-to-severe COPD …
Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV
MV Cossu, A D'Avolio, C Gervasoni… - Antimicrobial Agents …, 2024 - Am Soc Microbiol
Han and co-workers (1) recently presented the results of a phase 1 study evaluat ing the
pharmacokinetics and tolerability of long-acting injectable (LAI) rilpivirine and cabotegravir …
pharmacokinetics and tolerability of long-acting injectable (LAI) rilpivirine and cabotegravir …
[HTML][HTML] An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of activated PI3 kinase delta syndrome
…, M Beerahee, D Fernando, Y Karkera, C Sander… - Pulmonary …, 2023 - Elsevier
… 2–8 C to generate plasma. The resulting plasma samples were aliquoted into tubes and
frozen at approximately −20 C within 1 h of collection and were stored at −20 C until shipment to …
frozen at approximately −20 C within 1 h of collection and were stored at −20 C until shipment to …